Alpine Immune Sciences, Inc.

Equities

ALPN

US02083G1004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
64.97 ^USD	+0.02%		+0.05%	+240.87%

May. 10	Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone	MT
May. 09	Alpine Immune Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Alpine Immune Sciences, Inc. Appoints Andrew Sandler, MD as Chief Medical Officer of the Company, Effective August 17, 2022

August 11, 2022 at 04:05 pm EDT

Alpine Immune Sciences, Inc. announced that Andrew Sandler, MD was appointed as Chief Medical Officer of the company effective August 17, 2022. Dr. Sandler brings over 25 years of industry experience and clinical development expertise and leadership to the Alpine team. Dr. Sandler joins Alpine from Kiadis Pharma, where he was Chief Medical Officer.

Latest news about Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone	May. 10	MT
Alpine Immune Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
MOVES -Lazard hires veteran healthcare dealmaker Colocci as vice chairman	May. 09	RE
Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug	May. 06	DJ
North American Morning Briefing : Stock Futures -2-	Apr. 17	DJ
TD Cowen Downgrades Alpine Immune Sciences to Hold From Buy	Apr. 16	MT
North American Morning Briefing : Stock Futures -2-	Apr. 15	DJ
Leerink Partners Downgrades Alpine Immune Sciences to Market Perform From Outperform	Apr. 12	MT
North American Morning Briefing : Big Banks Kick -2-	Apr. 12	DJ
Health Care Slips on Risk Bias -- Health Care Roundup	Apr. 11	DJ
Wall Street rebounds on softer inflation data, eyes on earnings	Apr. 11	RE
Global markets live: Airbus, UBS, KKR, Meta Platforms, Tesla...	Apr. 11
Wolfe Research Downgrades Alpine Immune Sciences to Peer Perform From Outperform	Apr. 11	MT
Sector Update: Health Care Stocks Steady Pre-Bell Thursday	Apr. 11	MT
Will there be any Fed rate cuts this year?	Apr. 11
Nasdaq set for higher open as fresh inflation data allays rate jitters	Apr. 11	RE
Wholesale Prices Rise Less Than Expected in March as US Equity Futures Waver Pre-Bell	Apr. 11	MT
Sector Update: Health Care	Apr. 11	MT
HC Wainwright Downgrades Alpine Immune Sciences to Neutral From Buy, Raises Price Target to $65 From $50	Apr. 11	MT
Guggenheim Downgrades Alpine Immune Sciences to Neutral From Buy, Raises Price Target to $65 From $55	Apr. 11	MT
Wedbush Downgrades Alpine Immune Sciences to Neutral From Outperform, Raises Price Target to $65 From $47, Expects Vertex Deal to Close	Apr. 11	MT
Top Premarket Gainers	Apr. 11	MT
Vertex Pharmaceuticals' $4.9 Billion Deal for Alpine Shows Lead-Candidate's Potential, Analysts Say	Apr. 11	MT
Morgan Stanley Downgrades Alpine Immune Sciences to Equalweight From Overweight, Raises Price Target to $65 From $47	Apr. 11	MT
News Highlights : Top Company News of the Day - Thursday at 7 AM ET	Apr. 11	DJ

Chart Alpine Immune Sciences, Inc.

Duration

Period

More charts

Company Profile

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company, which is engaged in discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The Companyâs approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its ALPN-303 (povetacicept) is a dual antagonist of the B cell activating factor (BAFF) and a proliferation, inducing ligand (APRIL), cytokines, which play key roles in the pathogenesis of multiple autoimmune diseases via their contribution to the activation, differentiation and/or survival of B cells, particularly antibody-secreting cells, as well as T cells and innate immune cells. Its ALPN-101 (acazicolcept) is a dual Inducible T cell Costimulator (ICOS), and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Alpine Immune Sciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

64.97 USD

Average target price

62 USD

Spread / Average Target

-4.57%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ALPINE IMMUNE SCIENCES, INC.	+240.87%	4.46B
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	114B
REGENERON PHARMACEUTICALS, INC.	+11.84%	104B
BIONTECH SE	-14.15%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-4.16%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.28B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.55B

Bio Therapeutic Drugs